Piper Sandler Maintains Overweight on Boston Scientific, Raises Price Target to $62
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on Boston Scientific (NYSE:BSX) and raises the price target from $58 to $62.
July 06, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Boston Scientific and raises the price target from $58 to $62.
The raised price target by Piper Sandler indicates a positive outlook for Boston Scientific. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100